Table 3.
Selected clinical and laboratory features of patients 3 months after treatment.
| Parameters | Group 1 | Group 2 | Group 3 | Group 4 | P value |
|---|---|---|---|---|---|
| AST (IU/L) | 80.4 ± 14. 2 | 83.5 ± 6.74 | 76.36 ± 11.51 | 73.50 ± 9.25 | 0.679 |
| ALT (IU/L) | 55.90 ± 10.29 | 50.40 ± 8.75 | 51.3 ± 5.79 | 52.70 ± 12.56 | 0.380 |
| BIL-T (mg/dL) | 2.36 ± 0.63 | 2.54 ± 0.64 | 2.57 ± 0.42 | 2.19 ± 0.69 | 0.681 |
| BIL-D (mg/dL) | 1.10 ± 0.29 | 1.13 ± 0.28 | 1.06 ± 0.22 | 1.11 ± 0.25 | 0.927 |
| Albumin (g/dL) | 2.64 ± 0.31 | 2.66 ± 0.22 | 2.65 ± 0.34 | 2.60 ± 0.28 | 0.394 |
| PT (sec.) | 29.50 ± 6.02 | 28.7 ± 6.75 | 29.7 ± 4.85 | 29.0 ± 2.45 | 0.158 |
| BUN (mg/dL) | 73.1 ± 15.64 | 72.1 ± 14.7 | 65.8 ± 12.23 | 71.5 ± 11.02 | 0.333 |
| s.Cr (mg/dL) | 1.63 ± 0.29 | 1.68 ± 0.45 | 1.19 ± 0.26 | 1.71 ± 0.36 | 0.508 |
| Sodium (mEq/L) | 127.1 ± 4.79 | 127.4 ± 4.48 | 127.90 ± 4.53 | 127.10 ± 4.79 | 0.973 |
| Hemoglobin (g/dL) | 9.01 ± 0.78 | 8.77 ± 0.64 | 9.16 ± 0.72 | 8.53 ± 0.45 | 0.797 |
| RBCs (106/uL) | 3.39 ± 0.25 | 3.28 ± 0.37 | 3.37 ± 0.29 | 3.33 ± 0.30 | 0.960 |
| WBCs (103/uL) | 7.71 ± 1.29 | 8.01 ± 1.04 | 7.84 ± 1.33 | 8.15 ± 1.35 | 0.984 |
| Platelets (103/uL) | 74.43 ± 12.31 | 75.33 ± 5.86 | 74.88 ± 8.90 | 75.04 ± 6.95 | 0.995 |
| TNF-α (pg/mL) | 99.09 ± 15.92 | 73.42 ± 11.49 | 99.35 ± 17.51 | 59.42 ± 8.37 | 0.000 |
Data presented by mean ± SD; AST: Aspartate transaminase; ALT: Alanine aminotransferase; BIL-T: Total bilirubin; BIL-D: Direct bilirubin; PT: Prothrombin time; BUN: Blood urea nitrogen; s.Cr: Serum creatinine; RBCs: Red blood cells; WBCs: White blood cells; TNF-α: Tumor necrosis factor alpha; pg/mL: picograms per milliliter.